Israel's Health Basket Committee Begins 2027 Review with NIS 650 Million Budget
Translated & summarized from Hamal by baba
Israel's Health Basket Committee for 2027 has begun its work with a budget of NIS 650 million to evaluate new medications and medical technologies. Chaired by Prof. Dina Ben Yehuda, the committee will consider treatments for various cancers, obesity, rare diseases, and new vaccines. Health Minister Chaim Katz highlighted the budget's role in reducing access disparities, while Director General Moshe Bar Siman Tov stressed the committee's crucial responsibility in balancing needs with limited resources.
The story in 6 lines · by baba
- The 2027 Health Basket Committee has a budget of NIS 650 million to review new medical treatments.
- The committee will examine innovative therapies for various cancers, including bladder and breast cancer.
- Obesity treatments, such as Orforglipron and expanded Wegovy eligibility, are under consideration.
- New vaccines, early detection tests, and treatments for rare diseases are also on the agenda.
- Health Minister Chaim Katz aims to reduce disparities in access to advanced medical care.
- Prof. Dina Ben Yehuda chairs the committee, with Prof. Osnat Luxenburg serving as coordinator.
Israel's Public Committee for Expanding the Health Services Basket for 2027 was appointed on Sunday and will begin reviewing hundreds of new medications and medical technologies proposed for inclusion in the public health system. The committee has a budget of NIS 650 million to decide which treatments will be funded, considering medical, professional, social, and economic factors.
Chaired by Professor Dina Ben Yehuda, director of the Hematology Department at Hadassah Medical Center, and coordinated by Professor Osnat Luxenburg, head of the Ministry of Health's Medical Technologies, Information, and Research Division, the committee will examine a wide range of treatments. Notably, Professor Alon Pikarsky, who previously served on the committee and is Prime Minister Benjamin Netanyahu's physician, will not be a member this year.
Key areas for review include innovative cancer therapies, obesity treatments, medications for chronic and rare diseases, vaccines, and early disease detection tests. Specific cancer treatments under consideration include combination therapies for muscle-invasive bladder cancer and new drugs for breast cancer, such as Datrovy, Anher2, and Kisqali, which have shown promising results in clinical trials.
The committee will also discuss obesity treatments, including the oral medication Orforglipron and potential expanded eligibility for Wegovy for younger adults. Other proposals involve expanding the use of Mounjaro for patients with obesity alongside heart failure or sleep apnea.
Additional items on the agenda include the Beksaro vaccine against meningococcus B for infants, expanded public funding for eyeglasses for children up to age 10, and prenatal screening blood tests. The committee will also evaluate low-radiation CT scans for early lung cancer detection in at-risk workers and treatments for rare diseases like Rett syndrome and polycythemia vera, as well as a gene therapy for spinal muscular atrophy (SMA).
Health Minister Chaim Katz stated that the NIS 650 million annual addition to the health basket strengthens the state's response to its citizens and helps reduce disparities in access to new treatments. Director General of the Ministry of Health, Moshe Bar Siman Tov, emphasized the committee's significant responsibility in making complex decisions with limited resources, noting that their choices can improve quality of life and save lives.
Mentioned
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
